{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:10Z","timestamp":1792787950582,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern","id":[{"id":"https:\/\/ror.org\/02k7v4d05","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical trials are often analyzed using frequentist methods and results are interpreted according to their statistical significance. However, p-values and effect measures such as odds or hazard ratios are poorly understood by researchers and policymakers, and even less by patients and clinicians. Moreover, communicating uncertainty around treatment effects is challenging. Probabilistic statements from Bayesian analyses (e.g., the probability that a drug is more effective than placebo) offer an intuitive way to convey results and uncertainty, may provide insight, and support clinical decision-making. We aimed to (i) empirically evaluate the utility of probabilistic statements by re-analyzing data from previously published trials using Bayesian methods, and (ii) provide instructional examples of how probabilistic statements can be used to communicate and interpret results from clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data on primary outcomes obtained from trials previously published in leading medical journals, using Bayesian methods. We included 169 primary outcomes from 130 negative trials (p-values\u2009&gt;\u20090.05) across various medical fields, and 234 outcomes from 225 positive trials (p-value\u2009&lt;\u20090.05) in oncology. We used uninformative priors for illustration, supplementing them with skeptical priors in sensitivity analyses. We estimated the probabilities that active treatments were more effective or safe than controls, for each outcome. We also estimated probabilities that the treatment effects were above specific thresholds for clinical significance. We described three of the included trials in more detail and additionally analyzed one trial in neurology as didactical case studies, to illustrate the use of probabilistic statements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>So-called negative studies may sometimes yield clinically relevant evidence of an effect: in 26\/169 (15%) cases we found\u2009&gt;\u200990% probability that the experimental treatment is better than control; for 12\/169 (7%) of them, this probability was &gt;\u200995%. Conversely, positive trials may not always show evidence of clinically meaningful effects: in 25\/234 (11%) of the positive oncology trials, there was less than 50% probability that treatment reduces hazards by 20% or more. Our case studies illustrate how to use probabilistic statements in medical decision making in practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Relying on statistical significance without considering clinical importance can mislead decision-making and potentially harm patients. Probabilistic statements from Bayesian analyses can complement traditional approaches to communicating clinical trial results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-05208-w","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:19:56Z","timestamp":1791465596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bayesian probabilistic statements for communicating clinical trial results"],"prefix":"10.1186","volume":"24","author":[{"given":"Orestis","family":"Efthimiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Chalkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George CM","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Perneger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e8le","family":"Gayet-Ageron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"7748","key":"5208_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","volume":"567","author":"V Amrhein","year":"2019","unstructured":"Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305. https:\/\/doi.org\/10.1038\/d41586-019-00857-9.","journal-title":"Nature"},{"issue":"2","key":"5208_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA\u2019s Statement on p-Values: Context, Process, and Purpose. Am Stat. 2016;70(2):129\u201333. https:\/\/doi.org\/10.1080\/00031305.2016.1154108.","journal-title":"Am Stat"},{"key":"5208_CR3","doi-asserted-by":"publisher","unstructured":"Rovetta A, Mansournia MA. Common wrong beliefs about statistical testing: recent trends in biomedical sciences. Curr Opin Epidemiol Public Health. https:\/\/doi.org\/10.1097\/PXH.0000000000000054. doi:10.1097\/PXH.0000000000000054.","DOI":"10.1097\/PXH.0000000000000054"},{"key":"5208_CR4","doi-asserted-by":"publisher","unstructured":"Rovetta A, Piretta L, Mansournia MA. p-Values and confidence intervals as compatibility measures: guidelines for interpreting statistical studies in clinical research. Lancet Reg Health - Southeast Asia. 2025;33. https:\/\/doi.org\/10.1016\/j.lansea.2025.100534.","DOI":"10.1016\/j.lansea.2025.100534"},{"issue":"5","key":"5208_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/ije\/dyr099","volume":"40","author":"GC Siontis","year":"2011","unstructured":"Siontis GC, Ioannidis JP. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol. 2011;40(5):1292\u2013307. https:\/\/doi.org\/10.1093\/ije\/dyr099.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"5208_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/oby.2012.71","volume":"20","author":"GS Tajeu","year":"2012","unstructured":"Tajeu GS, Sen B, Allison DB, Menachemi N. Misuse of Odds Ratios in Obesity Literature: An Empirical Analysis of Published Studies. Obesity. 2012;20(8):1726\u201331. https:\/\/doi.org\/10.1038\/oby.2012.71.","journal-title":"Obesity"},{"issue":"1","key":"5208_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/2229-3485.173773","volume":"7","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: Absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7(1):51\u20133. https:\/\/doi.org\/10.4103\/2229-3485.173773 . PubMed PMID: 26952180; PubMed Central PMCID: PMC4763519.","journal-title":"Perspect Clin Res"},{"issue":"23","key":"5208_CR8","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1001\/jama.2023.8549","volume":"329","author":"T Perneger","year":"2023","unstructured":"Perneger T, Gayet-Ageron A. Evidence of Lack of Treatment Efficacy Derived From Statistically Nonsignificant Results of Randomized Clinical Trials. JAMA. 2023;329(23):2050\u20136. https:\/\/doi.org\/10.1001\/jama.2023.8549.","journal-title":"JAMA"},{"key":"5208_CR9","doi-asserted-by":"publisher","unstructured":"Lee JJ, Harrell FE, LaVange LM, Spiegelhalter DJ. Embracing Bayesian Methods in Clinical Trials: FDA\u2019s Long-Awaited Draft Guidance. JAMA. 2026 Mar;23. https:\/\/doi.org\/10.1001\/jama.2026.4179 . PubMed PMID: 41870893.","DOI":"10.1001\/jama.2026.4179"},{"issue":"6","key":"5208_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/sim.10000","volume":"43","author":"IC Marschner","year":"2024","unstructured":"Marschner IC. Confidence distributions for treatment effects in clinical trials: Posteriors without priors. Stat Med. 2024;43(6):1271\u201389. https:\/\/doi.org\/10.1002\/sim.10000 . PubMed PMID: 38205556.","journal-title":"Stat Med"},{"issue":"3","key":"5208_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s43441-022-00482-1","volume":"57","author":"R Bray","year":"2023","unstructured":"Bray R, Hartley A, Wenkert D, Muehlemann N, Natanegara F, Harrell FE, et al. Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers. Ther Innov Regul Sci. 2023;57(3):426\u201335. https:\/\/doi.org\/10.1007\/s43441-022-00482-1.","journal-title":"Ther Innov Regul Sci"},{"key":"5208_CR12","unstructured":"FDA, Center for Biologics Evaluation and Research. Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products [Internet]. FDA. 2026 [cited 2026 May 22]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-bayesian-methodology-clinical-trials-drug-and-biological-products"},{"issue":"3","key":"5208_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s43441-023-00515-3","volume":"57","author":"N Muehlemann","year":"2023","unstructured":"Muehlemann N, Zhou T, Mukherjee R, Hossain MI, Roychoudhury S, Russek-Cohen E. A Tutorial on Modern Bayesian Methods in Clinical Trials. Ther Innov Regul Sci. 2023;57(3):402\u201316. https:\/\/doi.org\/10.1007\/s43441-023-00515-3 . PubMed PMID: 37081374; PubMed Central PMCID: PMC10117244.","journal-title":"Ther Innov Regul Sci"},{"key":"5208_CR14","unstructured":"Spiegelhalter D, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation [Internet]. Wiley. DOI: 10.1002\/0470092602; [cited 2015 Dec 8]. Available from: http:\/\/eu.wiley.com\/WileyCDA\/WileyTitle\/productCd-0471499757.html"},{"key":"5208_CR15","unstructured":"Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials [Internet]. FDA. 2020 [cited 2025 Jun 30]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-use-bayesian-statistics-medical-device-clinical-trials"},{"issue":"3","key":"5208_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s43441-021-00357-x","volume":"57","author":"J Clark","year":"2023","unstructured":"Clark J, Muhlemann N, Natanegara F, Hartley A, Wenkert D, Wang F, et al. Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development. Ther Innov Regul Sci. 2023;57(3):417\u201325. https:\/\/doi.org\/10.1007\/s43441-021-00357-x . PubMed PMID: 34978048; PubMed Central PMCID: PMC8720547.","journal-title":"Ther Innov Regul Sci"},{"key":"5208_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.06.026","volume":"127","author":"TV Perneger","year":"2020","unstructured":"Perneger TV, Brindel P, Combescure C, Gayet-Ageron A. Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments. J Clin Epidemiol. 2020;127:1\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.06.026.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"5208_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jclinepi.2011.06.018","volume":"65","author":"ML Ferreira","year":"2012","unstructured":"Ferreira ML, Herbert RD, Ferreira PH, Latimer J, Ostelo RW, Nascimento DP, et al. A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. J Clin Epidemiol. 2012;65(3):253\u201361. https:\/\/doi.org\/10.1016\/j.jclinepi.2011.06.018 . PubMed PMID: 22014888.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"5208_CR19","doi-asserted-by":"publisher","first-page":"e300919","DOI":"10.1136\/bmjment-2023-300919","volume":"27","author":"E Sahker","year":"2024","unstructured":"Sahker E, Furukawa TA, Luo Y, Ferreira ML, Okazaki K, Chevance A, et al. Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. BMJ Ment Health. 2024;27(1):e300919. https:\/\/doi.org\/10.1136\/bmjment-2023-300919 . PubMed PMID: 38191234; PubMed Central PMCID: PMC10806871.","journal-title":"BMJ Ment Health"},{"issue":"12","key":"5208_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(12):1277\u201380. https:\/\/doi.org\/10.1200\/JCO. .2013.53.8009 PubMed PMID: 24638016.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"5208_CR21","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","volume":"388","author":"U Fischer","year":"2023","unstructured":"Fischer U, Koga M, Strbian D, Branca M, Abend S, Trelle S, et al. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med. 2023;388(26):2411\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2303048.","journal-title":"N Engl J Med"},{"issue":"7","key":"5208_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2024.1450","volume":"81","author":"MB Goeldlin","year":"2024","unstructured":"Goeldlin MB, Hakim A, Branca M, Abend S, Kneihsl M, Valenzuela Pinilla W, et al. Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial. JAMA Neurol. 2024;81(7):693\u2013702. https:\/\/doi.org\/10.1001\/jamaneurol.2024.1450 . PubMed PMID: 38805207; PubMed Central PMCID: PMC11134281.","journal-title":"JAMA Neurol"},{"key":"5208_CR23","doi-asserted-by":"publisher","unstructured":"Al-Hussainy N, Kragholm K, Lundbye-Christensen S, Torp-Pedersen C, Pareek M, Krohn Therkelsen S et al. Timing of anticoagulation restart after serious bleeding in atrial fibrillation. Heart 2025;heartjnl-2024-325343. https:\/\/doi.org\/10.1136\/heartjnl-2024-325343 PubMed PMID: 40670148.","DOI":"10.1136\/heartjnl-2024-325343"},{"key":"5208_CR24","doi-asserted-by":"publisher","unstructured":"Grekov P, Pustejovsky JE. A Gentle Introduction to Bayesian Posterior Predictive Checking for Single-Case Researchers. J Behav Educ 2026 Jan 17. https:\/\/doi.org\/10.1007\/s10864-025-09613-8","DOI":"10.1007\/s10864-025-09613-8"},{"issue":"9","key":"5208_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):833\u201342. https:\/\/doi.org\/10.1001\/jama.2021.0669 . PubMed PMID: 33651090; PubMed Central PMCID: PMC7926290.","journal-title":"JAMA"},{"issue":"2","key":"5208_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa2026983","volume":"385","author":"JA Deprest","year":"2021","unstructured":"Deprest JA, Benachi A, Gratacos E, Nicolaides KH, Berg C, Persico N, et al. Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia. N Engl J Med. 2021;385(2):119\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2026983.","journal-title":"N Engl J Med"},{"issue":"15","key":"5208_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne CH, L\u00e1ng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol. 2011;29(15):2011\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.33.5091.","journal-title":"J Clin Oncol"},{"key":"5208_CR28","doi-asserted-by":"publisher","unstructured":"Ostinelli EG, Efthimiou O, Agunbiade A, Naci H, Cipriani A. Communication of information on benefits and harms of multiple competing medical interventions: three-group, open-label, randomised controlled trial. Br J Psychiatry. 2026;1\u201311. https:\/\/doi.org\/10.1192\/bjp.2026.10555.","DOI":"10.1192\/bjp.2026.10555"},{"issue":"11","key":"5208_CR29","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1046\/j.1525-1497.2003.20928","volume":"18","author":"A Moxey","year":"2003","unstructured":"Moxey A, O\u2019Connell D, McGettigan P, Henry D. Describing treatment effects to patients. J Gen Intern Med. 2003;18(11):948\u201359. https:\/\/doi.org\/10.1046\/j.1525-1497.2003.20928. .x PubMed PMID: 14687282; PubMed Central PMCID: PMC1494946.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"5208_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/M14-0295","volume":"161","author":"DA Zipkin","year":"2014","unstructured":"Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161(4):270\u201380. https:\/\/doi.org\/10.7326\/M14-0295 . PubMed PMID: 25133362.","journal-title":"Ann Intern Med"},{"issue":"4","key":"5208_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jclinepi.2009.06.003","volume":"63","author":"SR Johnson","year":"2010","unstructured":"Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol. 2010;63(4):355\u201369. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.003 . PubMed PMID: 19716263.","journal-title":"J Clin Epidemiol"},{"key":"5208_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.envsoft.2013.10.010","volume":"52","author":"DE Morris","year":"2014","unstructured":"Morris DE, Oakley JE, Crowe JA. A web-based tool for eliciting probability distributions from experts. Environ Model Softw. 2014;52:1\u20134. https:\/\/doi.org\/10.1016\/j.envsoft.2013.10.010.","journal-title":"Environ Model Softw"},{"key":"5208_CR33","unstructured":"Oakley J. SHELF: Tools to Support the Sheffield Elicitation Framework [Internet]. 2026 [cited 2026 May 22]. Available from: https:\/\/cran.r-project.org\/web\/packages\/SHELF\/index.html"},{"issue":"17","key":"5208_CR34","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.4244\/EIJ-D-25-00147","volume":"21","author":"GCM Siontis","year":"2025","unstructured":"Siontis GCM, Efthimiou O. A Bayesian analysis of invasive treatment strategies for elderly patients with acute coronary syndromes. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2025;21(17):e1037\u20139. https:\/\/doi.org\/10.4244\/EIJ-D-25-00147 . PubMed PMID: 40887983; PubMed Central PMCID: PMC12378594.","journal-title":"EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05208-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05208-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05208-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:19:57Z","timestamp":1791465597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05208-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5208"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05208-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"554"}}